about
De novo glomerular diseases after renal transplantationGlomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI.Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis.A best practice position statement on pregnancy in chronic kidney disease: the Italian Study Group on Kidney and Pregnancy.Combination treatment in autoimmune diseases: systemic lupus erythematosus.Long-term prognosis of diffuse proliferative glomerulonephritis associated with infection in adults.Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis.TLR-4 and VEGF polymorphisms in chronic periaortitisThe value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy.Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens.Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference.Pregnancy after lupus nephritis.Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy.Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE).De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review.Rapidly progressive crescentic glomerulonephritis: Early treatment is a must.The multifaceted aspects of refractory lupus nephritis.Pregnancies in women receiving renal transplant for lupus nephritis: description of nine pregnancies and review of the literature.Best practices on pregnancy on dialysis: the Italian Study Group on Kidney and Pregnancy.Pregnancy in women with systemic lupus erythematosus (SLE).Remission and withdrawal of therapy in lupus nephritis.Lupus nephritis: When and how often to biopsy and what does it mean?Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis.Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.Rituximab therapy for primary glomerulonephritis: Report on two casesOxidative stress and homocysteine metabolism in patients with lupus nephritis.Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients.The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival.The long-term prognosis of renal transplant in patients with systemic vasculitis.IL-10-producing forkhead box protein 3-negative regulatory T cells inhibit B-cell responses and are involved in systemic lupus erythematosus.The long-term prognosis of renal transplantation in patients with lupus nephritis.Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up.Value of a commercial kit for detecting anti-C1q autoantibodies and correlation with immunological and clinical activity of lupus nephritis.Treatment of membranous lupus nephritis."Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches.Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study.The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis.Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study.
P50
Q27005877-6D719C9C-9B10-41CF-8EF2-A4B17F217CF7Q30596600-CF479DF2-B025-478D-8EA3-658AF421A3F8Q33358476-41AF8E86-6DEB-4328-89C9-0019C09E9FA2Q33844319-2967CFC6-E71F-414E-AC16-B9089984B148Q34309764-C56E8091-DA41-452C-AD45-D746549B7F3CQ34647791-1C70A55A-3247-466A-BBB0-D10917FA489FQ34654452-8FCE840F-D26D-4455-8DE6-001CA1C17683Q34729825-84BAD94C-B2C2-4CBE-8405-B2E6F720883CQ35169740-86411B10-3ABF-419F-B5C6-EA94E5EFCA4DQ35422370-4652541B-D78A-43B3-A12F-D7B6DE4534E3Q35608355-5DB7EFB0-1123-4F01-A726-BE92813C6B5DQ36054888-551B19ED-B69C-4ADC-AA76-18614E8F9541Q36199508-CB620B54-68F8-41D5-9D16-D6207A78E1D9Q37709460-8CBCA9BB-DF94-41DB-9D8F-D0F20A7D0E79Q38169598-5C430BD8-F6FB-4576-93A9-ACB34DFB5A26Q38189959-5B8DA351-9567-48F5-AA2F-96E46A8A7EEFQ38198465-EAE23521-0C9A-4D58-AC28-F89E68F90A7DQ38285375-B7DF0538-7A94-4BBE-88BE-7461B346C6EDQ38440086-BA301382-0478-4F77-8C7D-96E7918DCD22Q38475830-3C0DDF36-6A06-4BA2-9641-6419ADDDCA5DQ38824614-F9757792-3737-462E-BD72-03A23ABB83FAQ38826018-0C493E80-FAC4-42EA-80D0-CC8C0835992FQ38878698-2F4E6484-1C93-4D72-AA6B-BEFC02C0D267Q40338767-6E9D09EE-25C6-40E3-B634-C558F2337833Q40663445-284BA7F7-E92D-4B89-A67D-FC9997DDD1FAQ41036642-04CDF202-EC73-49F2-939A-1624FF03A3D3Q43236764-6D17BDCF-0FD4-42C2-8A42-AF88C0C32FC0Q43635713-670EC3A4-B449-4930-897A-02E0C6652001Q43654750-63B060E7-C544-443F-93AE-69C6F4A1953FQ45165303-9C5722EC-1E7D-4765-B5F3-93BF0EED9309Q45878883-DC22DE8C-F11C-4261-8041-6DF6CF9DB868Q46463548-2CBC6FAE-7CE4-4539-9FB0-22ED7940D445Q46925614-F5D56E6F-D660-4146-8388-4DA8E1480705Q50448184-A5A4BA96-C55C-422B-8E47-E51066591DBBQ50898046-671A768E-2304-4633-A6C9-BFB2A4F4E823Q50988300-8FB53C9A-CDB2-4EF0-96FB-02A24ED147E5Q51201388-425F85BA-2478-4D5C-8963-AACF4582986FQ51591514-38672122-E88A-41A8-B061-A7851F22B918Q53151772-179F1B72-CBDF-477C-B661-1C75A641E291Q54671112-4A51F7B4-93A8-4FDB-98CE-F5FA5088E66A
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0003-4955-6061
@en
name
Gabriella Moroni
@ast
Gabriella Moroni
@en
Gabriella Moroni
@es
Gabriella Moroni
@nl
Gabriella Moroni
@sl
type
label
Gabriella Moroni
@ast
Gabriella Moroni
@en
Gabriella Moroni
@es
Gabriella Moroni
@nl
Gabriella Moroni
@sl
prefLabel
Gabriella Moroni
@ast
Gabriella Moroni
@en
Gabriella Moroni
@es
Gabriella Moroni
@nl
Gabriella Moroni
@sl
P1053
J-8183-2015
P106
P21
P31
P3829
P496
0000-0003-4955-6061